Fluorouracil injection and oral

Red

Brand Name(s):

Indication:Common malignancies .

Rationale:1,2,3

Considered:Jul-09

Review Date:Jul-23

Comments:
Saftey update 2020 – Pharmacovigilance Risk Assessment Committee (PRAC) provides new testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine. Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment-lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.